Onpattro

Active Ingredient(s): Patisiran
FDA Approved: * August 10, 2018
Pharm Company: * ALNYLAM PHARMA INC
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Onpattro Overview

Patisiran (trade name Onpattro) is a medication for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis. It is the first small interfering RNA-based drug approved by the FDA. Through this mechanism, it is a gene silencing drug that interferes with the production of an abnormal form of transthyretin. During its development, patisiran was granted orphan drug status, fast track designation, priority review and breakthrough therapy designation due to its ...

Read more Onpattro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Patisiran

Recent Onpattro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Onpattro: (1 result)

Sorted by National Drug Code

• 71336-1000 Onpattro 2 mg/ml Intravenous Injection, Lipid Complex by Alnylam Pharmaceuticals, Inc.

Other drugs which contain Patisiran or a similar ingredient: (1 result)

• PATISIRAN